A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935

The drug being tested in this study is called TAK-935. TAK-935 is being tested to examine
the degree and duration of brain CH24H enzyme occupancy/target engagement as a function of
TAK-935 plasma concentration in order to guide dosing and schedule for future clinical
trials with TAK-935.This study will utilize the PET ligand [18F]MNI-792 to evaluate the
brain CH24H occupancy of TAK-935 after single dose oral administration in healthy adult
participants. The study will evaluate up to 16 participants. The first 2 participants will
take TAK-935 600 mg oral solution and undergo PET imaging using tracer [18F]MNI-792 up to 5
microgram (up to 370 MBq), injection, intravenously prior to each PET scan at Baseline, 45
minutes and 10 hours post-TAK-935 dose. TAK-935 dose and timing of post-dose scans for
subsequent participants will be based on the data from the previous participants. This
single-center trial will be conducted in the United States. The overall time to participate
in this study is up to 55 days. Participants will make 4 visits to the clinic, including 2
confinement periods to the clinic for PET imaging. Participants will be contacted by phone
on Day 22 for follow-up safety assessments.

Inclusion Criteria:

1. In the opinion of the investigator, is capable of understanding and complying with
protocol requirements.

2. Signs and dates a written, informed consent form and any required privacy
authorization prior to the initiation of any study procedures including requesting
that a participant fast for any laboratory evaluations.

3. Is a healthy male or female and aged 19 to 55 years, inclusive, at the time of
informed consent and first study medication dose.

4. Weighs at least 45 kilogram (kg) and has a body mass index (BMI) from 18.0 to 30.0
kilogram per square meter (kg/m^2), inclusive at Screening.

5. A female of non-bearing potential (example post-menopausal by history; or history of
hysterectomy, bilateral salpingectomy, or oophorectomy).

Exclusion Criteria:

1. Have a known history or evidence of a clinically significant disorder (including
neurologic and psychiatric), or disease that in the opinion of the study investigator
would pose a risk to the participant safety or interfere with the study evaluation,
procedures or completion.

2. Contraindication to magnetic resonance imaging (MRI) based on the standard MRI
radiography screening questionnaire.

3. Had exposure to any radiation greater than (>) 15 millisievert (mSv)/year (example,
occupational or radiation therapy) within the previous year prior to Baseline
imaging.

4. Has a known hypersensitivity to any component of the formulation of TAK-935 or
related compounds, or to [18F]MNI-792 or to any of its components.

5. Clinically significant abnormal findings on brain MRI scan or findings on brain MRI
that may interfere with the interpretation of the PET imaging.

6. Use of any over-the-counter, herbal, or prescription medications or supplements
within 30 days prior to baseline imaging.